Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection

In this randomized clinical trial of 81 participants who had completed treatment for a CDI and were taking systemic antibiotics for a non-CDI indication, recurrent CDI occurred in 43.6% of participants in the oral vancomycin group vs 57.1% in the placebo group at 8 weeks. However, the study was underpowered and this difference did not reach statistical significance.